Untitled

Becker, Richard C.; Burns, Maureen; Gore, Joel M.; Lambrew, Costas T.; French, William J.; Rogers, William J.

doi:10.1023/a:1018706425864

Cited by 18 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that complications or dysfunctions of liver and kidney limit the use of statins and ACEI/ ARB drugs [ 17 , 18 ]. Concerns regarding the risk of bleeding and gastrointestinal discomfort limit the use of aspirin in elderly patients [ 20 , 21 ]. Similar with previous foreign reports [ 3 , 22 , 23 ], our study suggests that EBM compliance among Chinese patients with CAD is notably inadequate.…”

Section: Discussionmentioning

confidence: 99%

The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: a retrospective cohort study

Xia

Huang

et al. 2018

BMC Public Health

View full text Add to dashboard Cite

BackgroundElderly patients with coronary artery disease (CAD) frequently complicated with more cardiovascular risk factors, but received fewer evidence-based medications (EBMs). This study explored the association of EBMs compliance in different age groups and the risk of long-term death.MethodsA retrospective analysis was conducted from a single registered database. 2830 consecutive patients with CAD were enrolled and grouped into 3 categories by age. The primary end point was all-cause mortality and secondary endpoint is cardiovascular mortality.ResultsThe mean follow-up time was 30.25 ± 11.89 months and death occurred in 270 cases,including 150 cases of cardiac death. Cumulative survival curves indicated that the incidence rates of all-cause death and cardiovascular death increased with age (older than 75 years old vs. 60 to 75 years old vs. younger than 60 years old, mortality: 18.7% vs. 9.6% vs. 4.1%, p < 0.001; cardiovascular mortality: 10.3% vs. 5.1% vs. 2.7%, p < 0.001). The percentage of elderly patients using no EBMs was significantly higher than the percentages in the other age group (7.7% vs. 4.6% vs. 2.2%,p < 0.05). Cox regression analysis revealed the benefit of combination EBMs (all-cause mortality: hazard ratio [HR] 0.15, 95% CI 0.08–0.27; cardiac mortality: HR 0.08, 95% CI 0.04–0.19) for older CAD patients. Similar trends were found about different kinds of EBMs in elderly patients.ConclusionsElderly patients with CAD had higher risk of death but a lower degree of compliance with EBMs usage. Elderly CAD patients could receive more clinical benefits by using EBMs.Electronic supplementary materialThe online version of this article (10.1186/s12889-018-5049-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: a retrospective cohort study

Xia

Huang

et al. 2018

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…Consistent with previous studies, older patients were less likely to receive early aspirin. 14 – 15 This may reflect concerns about the risk of bleeding. However, while elderly patients may be at high risk for adverse consequences of therapy, their risks for adverse consequences of no treatment are also likely substantially higher; a study reported that in elderly patients, the use of aspirin was associated with 22% lower odds of 30‐day mortality, which exceeded 20% in the older population.…”

Section: Discussionmentioning

confidence: 99%

Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study

Gao

et al. 2014

JAHA

View full text Add to dashboard Cite

BackgroundAspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources. However, the rates and recent trends of aspirin use for the early treatment of AMI in China are unknown.Methods and ResultsUsing data from the China Patient‐centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE‐Retrospective AMI Study), we identified a cohort of 14 041 patients with AMI eligible for early aspirin therapy. Early use of aspirin for AMI increased over time (78.4% in 2001, 86.5% in 2006, and 90.0% in 2011). However, about 15% of hospitals had a rate of use of <80% in 2011. Treatment was less likely in patients who were older, presented with cardiogenic shock at admission, presented without chest discomfort, had a final diagnosis of non‐ST‐segment elevation acute myocardial infarction, or did not receive reperfusion therapy. Hospitalization in rural regions was also associated with aspirin underuse.ConclusionsDespite improvements in early use of aspirin for AMI in China, there remains marked variation in practice and opportunities for improvement that are concentrated in some hospitals and patient groups.Clinical Trial RegistrationURL: ClinicalTrials.gov Unique identifier: NCT01624883.

show abstract

“…The impossibility of staying current in practice is reflected in the nearly generational (17 years) delay between a definitive clinical trial and changing the majority of clinical practice (34). Even something as life-saving, safe, inexpensive, and simple as aspirin in the setting of an acute myocardial infarction was still not given to 1 of every 4 people admitted to the hospital with a ST-segment elevation myocardial infarction a full 9 years after the publication of ISIS-2 in 1987 (35). Accepting that we cannot possibly stay current is the first step toward fully embracing the potential of digital technology to improve the quality of care we can provide.…”

Section: Improving Physician Carementioning

confidence: 99%

Moving From Digitalization to Digitization in Cardiovascular Care

Steinhubl

Topol

2015

Journal of the American College of Cardiology

View full text Add to dashboard Cite

So far, the digitization of health care is best exemplified by electronic medical records, which have been far from favorably or uniformly accepted. However, properly implemented digitization can enable better patient outcomes, improve convenience, potentially lower health care costs, and possibly lead to much greater physician satisfaction. Precision (also known as personalized or individualized) medicine is frequently discussed today, but, in reality, it is what physicians have attempted to do as best they could for millennia. But now we have new tools that can begin to give us a much more high-definition view of our patients; from affordable and rapid genetic testing to wearable sensors that track a wide range of important physiologic parameters continuously. Although seemingly counterintuitive, the digitization of health care can also markedly improve the physician-patient relationship, allowing more time for human interaction when care is bolstered by digital technologies that better individualize diagnostics and treatments.

show abstract

Untitled

Cited by 18 publications

References 22 publications

The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: a retrospective cohort study

The impact of age on the implementation of evidence-based medications in patients with coronary artery disease and its prognostic significance: a retrospective cohort study

Trends in Early Aspirin Use Among Patients With Acute Myocardial Infarction in China, 2001–2011: The China PEACE‐Retrospective AMI Study

Moving From Digitalization to Digitization in Cardiovascular Care

Contact Info

Product

Resources

About